| Objective:Through the observation of advanced non-small cell lung cancer patients TKI before and after treatment in
peripheral blood IgG, IgM, IgA, C3, C4, C-reaction protein and CD3+, CD4+, CD8+, CD4+ /CD8+cell expression changes, we discuss TKI
treatment for advanced non-small cell lung cancer on the immune function of influence and significance.Methods:30 cases of no n-small
cell lung cancer patients were selected and their following factors were detected before treatment and after one month of therapy by
hydrochloric acid erlotinib (TKI), peripheral IgG, IgM, IgA, C3, C4, C-reaction protein and CD3+, CD4+, CD8+, CD4+/CD8+ cells express
level, analyzes its expression changes and the relationship between changes and the therapy efficacy. 30 patients in non-small cell lung
cancer patients were as control group.Results:Before treatment, TKI group and control group IgG, IgM, IgA, C3, C4, C - reaction protein
level essentially normal, but the number of CD4+ cells reduced, CD4+/CD8+ ratio was low, CD8+ cells quantity increased, compared two
groups, IgG, IgM, IgA, C3, C4, C-reaction protein, CD3+, CD4+, CD8+, CD4+/CD8+ differences were no statistical significance (P>0.05);
TKI treatment after a month, TKI group and control group IgG, IgM, IgA, C3, C4, C - reaction protein level had no obvious change, but
the number CD4+ cells increased, CD4+/CD8+ ratio is previously high, the CD8+ cells quantity is reduced, compared two groups, CD3+,
IgG, IgM, IgA, C3, C4, C - reaction protein difference were not statistically significant (P>0.05), but CD4+, CD4++/CD8+, CD8+difference
have statistical significance (P<0.01).Conclusion:After TKI treatment, advanced non-small cell lung cancer patients with cell immune
function has been improved with the changes of the CD4+ and CD8+ cells , and TKI treatment efficacy can be relatively peripheral blood
CD4+,CD4+/CD8+,CD8+cellsexpressionchanges reflected. |
